Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019)...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 10; p. 2817
Main Authors Wijetunga, Imeshi, McVeigh, Laura E, Charalambous, Antonia, Antanaviciute, Agne, Carr, Ian M, Nair, Amit, Prasad, K Raj, Ingram, Nicola, Coletta, P Louise
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 30.09.2020
MDPI
Subjects
Bile ducts
Bioinformatics
Biomarkers
Cancer
Cancer therapies
Cholangiocarcinoma
Diagnosis
Disease
Gelatinase B
Genes
Genetic translation
Growth factors
Health aspects
Medical prognosis
Nanoparticles
Nanotechnology
Ontology
Proteins
Rare diseases
Review
Reviews
Systematic review
Japan
therapy and diagnosis
theranosis
cholangiocarcinoma
biomarkers
biomarker selection
Online AccessGet full text

Cover

Abstract Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.
AbstractList Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.
Bile duct cancers are rare cancers that have poor prospects and limited treatment options. Recently, significant advances have been made in the field of nanomedicine which has allowed new approaches to the diagnosis and treatment (i.e., theranosis) of human diseases. To develop nanomedicines that could earmark or target bile duct cancer, specific proteins (or biomarkers) that are present in bile duct cancer but absent in normal tissues are required. We conducted a systematic search of the published literature for bile duct cancer biomarkers that would be suitable for theranosis. Specialist bioinformatics tools were used to help categorize the resulting data set. To select the most promising biomarkers from the search, biomarkers were ranked according to a theranosis-scoring-system and then evaluated in detail. The biomarkers identified using this approach have the potential to promote targeted nanomedicine-based systems to treat bile duct cancers.
Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.
Simple SummaryBile duct cancers are rare cancers that have poor prospects and limited treatment options. Recently, significant advances have been made in the field of nanomedicine which has allowed new approaches to the diagnosis and treatment (i.e., theranosis) of human diseases. To develop nanomedicines that could earmark or target bile duct cancer, specific proteins (or biomarkers) that are present in bile duct cancer but absent in normal tissues are required. We conducted a systematic search of the published literature for bile duct cancer biomarkers that would be suitable for theranosis. Specialist bioinformatics tools were used to help categorize the resulting data set. To select the most promising biomarkers from the search, biomarkers were ranked according to a theranosis-scoring-system and then evaluated in detail. The biomarkers identified using this approach have the potential to promote targeted nanomedicine-based systems to treat bile duct cancers.AbstractCholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996–2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.
Audience Academic
Author Charalambous, Antonia
Nair, Amit
Ingram, Nicola
Wijetunga, Imeshi
Coletta, P Louise
McVeigh, Laura E
Carr, Ian M
Antanaviciute, Agne
Prasad, K Raj
AuthorAffiliation 2 Department of Hepatobiliary and Transplant Surgery, St. James’s University Hospital, Leeds LS9 7TF, UK; raj.prasad@nhs.net
1 Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds LS9 7TF, UK; i.wijetunga@nhs.net (I.W.); 20mcveigh@gmail.com (L.E.M.); antonia.charalambous11@gmail.com (A.C.); agne.antanaviciute@ndm.ox.ac.uk (A.A.); i.m.carr@leeds.ac.uk (I.M.C.); nair.amit@doctors.org.uk (A.N.); n.ingram@leeds.ac.uk (N.I.)
AuthorAffiliation_xml – name: 2 Department of Hepatobiliary and Transplant Surgery, St. James’s University Hospital, Leeds LS9 7TF, UK; raj.prasad@nhs.net
– name: 1 Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James’s University Hospital, Leeds LS9 7TF, UK; i.wijetunga@nhs.net (I.W.); 20mcveigh@gmail.com (L.E.M.); antonia.charalambous11@gmail.com (A.C.); agne.antanaviciute@ndm.ox.ac.uk (A.A.); i.m.carr@leeds.ac.uk (I.M.C.); nair.amit@doctors.org.uk (A.N.); n.ingram@leeds.ac.uk (N.I.)
Author_xml – sequence: 1
  givenname: Imeshi
  orcidid: 0000-0002-4128-7381
  surname: Wijetunga
  fullname: Wijetunga, Imeshi
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 2
  givenname: Laura E
  orcidid: 0000-0001-9417-8632
  surname: McVeigh
  fullname: McVeigh, Laura E
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 3
  givenname: Antonia
  orcidid: 0000-0001-5895-3697
  surname: Charalambous
  fullname: Charalambous, Antonia
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 4
  givenname: Agne
  surname: Antanaviciute
  fullname: Antanaviciute, Agne
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 5
  givenname: Ian M
  orcidid: 0000-0001-9544-1068
  surname: Carr
  fullname: Carr, Ian M
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 6
  givenname: Amit
  orcidid: 0000-0003-1344-392X
  surname: Nair
  fullname: Nair, Amit
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 7
  givenname: K Raj
  surname: Prasad
  fullname: Prasad, K Raj
  organization: Department of Hepatobiliary and Transplant Surgery, St. James's University Hospital, Leeds LS9 7TF, UK
– sequence: 8
  givenname: Nicola
  surname: Ingram
  fullname: Ingram, Nicola
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
– sequence: 9
  givenname: P Louise
  surname: Coletta
  fullname: Coletta, P Louise
  organization: Leeds Institute of Medical Research, Wellcome Trust Brenner Building, St James's University Hospital, Leeds LS9 7TF, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33007872$$D View this record in MEDLINE/PubMed
BookMark eNpdkUtLAzEUhYMoPqprdzLgxk01r0kyLoRafIGgaF2HNHOnjU4TTaYV_72R-s4mgfudc3M4W2jVBw8I7RJ8yFiFj6zxFmIilGCqiFxBmxRL2hei4qu_3htoJ6VHnA9jRAq5jjYYw1gqSTfR7Sgan1rTOT8pTl2YmfiUPYvQFMNpaI2fuGBNtM7nUdGEWIymkCUhuXRcDIr7t9TBLMttcQcLB6_baK0xbYKdz7uHHs7PRsPL_vXNxdVwcN23nFdd3wrV1ETWjI8bUgqlmJWcEiYIBVZxDOMaKw6E1VVpTSnAqnHNhWGWmKqUDeuhk6Xv83w8g9qC76Jp9XN0OcKbDsbpvxPvpnoSFloKTCSpssHBp0EML3NInZ65ZKHNmSHMk6acK46F4Dyj-__QxzCPPsfTtOSyZJmlP9TEtKCdb0Leaz9M9UBwKoUSimXqaEnZGFKK0Hx_mWD9Uav-V2tW7P1O-s1_lcjeARjLoDc
CitedBy_id crossref_primary_10_3389_fchem_2021_699284
crossref_primary_10_3390_cancers13040919
crossref_primary_10_1177_00031348221124323
crossref_primary_10_3389_fgene_2022_868015
Cites_doi 10.1056/NEJMoa0908721
10.1016/j.ccr.2005.03.003
10.1111/j.1365-2559.1994.tb01570.x
10.2967/jnumed.115.154401
10.1080/14737140.2018.1502664
10.1002/cncr.27788
10.3390/ijms19041004
10.1016/j.ijpharm.2009.04.026
10.1016/j.biocel.2003.12.002
10.3389/fphar.2018.00404
10.1038/sj.bjc.6604129
10.1038/bjc.2011.199
10.1007/s10654-010-9491-z
10.1002/med.21299
10.1016/0092-8674(86)90374-0
10.1007/s00259-019-04555-6
10.1016/S1470-2045(07)70044-X
10.1038/ncpgasthep0389
10.1053/gast.1997.v112.pm9024293
10.1093/nar/gks1118
10.1038/s41575-020-0310-z
10.3892/or.2014.3261
10.1074/jbc.M800938200
10.1186/s13000-015-0445-3
10.21873/anticanres.13043
10.1038/onc.2010.455
10.1158/1078-0432.CCR-08-1547
10.1016/j.cld.2020.04.005
10.1038/s41596-019-0128-8
10.1007/s00428-014-1705-4
10.1136/jcp.2005.033712
10.1128/MCB.21.21.7380-7390.2001
10.4103/0975-7406.137249
10.1093/nar/gky1131
10.1007/s00428-019-02624-7
10.3748/wjg.v13.i48.6470
10.1016/S0140-6736(13)61903-0
10.1073/pnas.0908301106
10.1371/journal.pone.0163366
10.1093/jnci/djy088
10.1038/s41598-019-49860-0
10.1007/s12079-009-0075-1
10.1038/s41598-018-27454-6
10.1111/liv.14095
10.1186/1471-2407-10-631
10.1038/s41388-018-0485-8
10.1002/advs.201701070
10.7150/thno.10657
10.1158/0008-5472.CAN-16-3247
10.1146/annurev-anchem-061516-045205
10.1007/s00428-011-1092-z
10.7150/thno.6592
10.1097/MPA.0000000000001195
10.1021/acsnano.6b06040
10.1016/j.pathol.2015.11.011
10.2967/jnumed.114.146019
10.2310/7290.2008.00010
10.1111/nyas.13360
10.1111/jgh.12620
10.1186/s12885-019-5429-3
10.18632/oncotarget.16723
10.1111/his.13797
10.1186/s40644-019-0234-4
10.2147/IJN.S165210
10.1590/0100-6991e-20181826
10.2967/jnumed.114.149484
10.1016/j.critrevonc.2020.102975
10.2353/ajpath.2009.080012
10.1159/000113490
10.1111/apm.12919
10.1016/j.bbapap.2009.07.027
10.1038/labinvest.2009.89
10.1093/protein/gzu007
10.1016/j.humpath.2009.10.002
10.1097/01.sla.0000201452.09591.f3
10.18632/oncotarget.1943
10.1007/s00259-013-2679-1
10.1016/j.ejso.2018.01.012
10.1007/s12253-014-9806-6
10.18632/oncotarget.19196
10.1007/s11864-015-0366-0
10.1593/tlo.10220
10.1021/acs.chemrev.5b00148
10.1158/1078-0432.CCR-05-1302
10.1080/19336918.2014.1000075
10.1159/000207506
10.1159/000453013
10.1097/CCM.0b013e3181921349
10.1093/nar/gky1038
10.1371/journal.pone.0187767
10.7150/ijms.10083
ContentType Journal Article
Copyright COPYRIGHT 2020 MDPI AG
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2020 by the authors. 2020
Copyright_xml – notice: COPYRIGHT 2020 MDPI AG
– notice: 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2020 by the authors. 2020
DBID NPM
AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers12102817
DatabaseName PubMed
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Publicly Available Content (ProQuest)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID A642768683
10_3390_cancers12102817
33007872
Genre Journal Article
Review
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: Engineering and Physical Sciences Research Council
  grantid: EP/L504993/1
– fundername: Engineering and Physical Sciences Research Council
  grantid: EP/I000623/1
– fundername: Medical Research Council
  grantid: MR/L01629X
– fundername: Engineering and Physical Sciences Research Council
  grantid: EP/P023266/1
– fundername: Rays of Hope: The Yorkshire Liver Research Fund
  grantid: Charity registration 1170369
GroupedDBID ---
3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
ABDBF
ABUWG
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
NPM
OK1
P6G
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RPM
TUS
AAYXX
CITATION
7T5
7TO
7XB
8FK
H94
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c449t-c68fd17d34bf156883c74213612e3940ebd084e13d95ca56ec8bd46a3c1a957f3
IEDL.DBID RPM
ISSN 2072-6694
IngestDate Tue Sep 17 21:22:09 EDT 2024
Thu Dec 05 22:53:02 EST 2024
Thu Oct 10 17:56:37 EDT 2024
Tue Nov 19 20:47:36 EST 2024
Fri Dec 06 09:26:09 EST 2024
Sat Nov 02 12:24:31 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords therapy and diagnosis
theranosis
cholangiocarcinoma
biomarkers
biomarker selection
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c449t-c68fd17d34bf156883c74213612e3940ebd084e13d95ca56ec8bd46a3c1a957f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-4128-7381
0000-0003-1344-392X
0000-0001-9544-1068
0000-0001-9417-8632
0000-0001-5895-3697
0000-0001-5274-8502
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601719/
PMID 33007872
PQID 2547532442
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7601719
proquest_miscellaneous_2448406644
proquest_journals_2547532442
gale_infotracmisc_A642768683
crossref_primary_10_3390_cancers12102817
pubmed_primary_33007872
PublicationCentury 2000
PublicationDate 20200930
PublicationDateYYYYMMDD 2020-09-30
PublicationDate_xml – month: 9
  year: 2020
  text: 20200930
  day: 30
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Cancers
PublicationTitleAlternate Cancers (Basel)
PublicationYear 2020
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References ref_93
Espinoza (ref_105) 2019; 74
Jeelani (ref_14) 2014; 6
Valle (ref_9) 2010; 362
Tian (ref_10) 2020; 19
Pene (ref_12) 2009; 37
Tiede (ref_85) 2014; 27
Sauerbrei (ref_104) 2018; 110
Patel (ref_1) 2006; 3
Scherer (ref_35) 2008; 7
Homayouni (ref_92) 2017; 8
Wu (ref_21) 2013; 3
Bensch (ref_37) 2015; 56
Kirstein (ref_6) 2016; 32
ref_25
Mackie (ref_75) 1986; 47
Lundin (ref_82) 2007; 72
Dottermusch (ref_73) 2019; 475
Hilvo (ref_87) 2008; 283
Padthaisong (ref_64) 2017; 37
Leppanen (ref_78) 2019; 48
ref_29
Simbolo (ref_61) 2014; 5
ref_27
(ref_74) 2004; 36
Kelloff (ref_19) 2005; 11
Merla (ref_98) 2015; 16
Cheal (ref_94) 2014; 41
Idee (ref_13) 2013; 3
Shi (ref_43) 2013; 119
Zhao (ref_67) 2019; 19
Park (ref_47) 2018; 44
Tian (ref_45) 2015; 21
Gu (ref_60) 2012; 59
Price (ref_96) 2018; 18
Szklarczyk (ref_28) 2019; 47
Niimi (ref_71) 2001; 21
Wu (ref_20) 2015; 12
Wiangnon (ref_5) 2011; 12
Supuran (ref_91) 2010; 1804
Subimerb (ref_42) 2010; 3
Mi (ref_26) 2013; 41
Yang (ref_62) 2014; 32
Xu (ref_79) 2015; 10
Divgi (ref_33) 2007; 8
He (ref_84) 2018; 5
Schmitz (ref_55) 2007; 13
Ettrich (ref_11) 2019; 9
Chen (ref_16) 2016; 116
Leppanen (ref_80) 2017; 8
Iguchi (ref_50) 2009; 76
ref_57
ref_52
ref_51
Qi (ref_81) 2019; 127
Gu (ref_53) 2015; 8
Midwood (ref_77) 2009; 3
Franz (ref_106) 2015; 9
Onodera (ref_41) 2009; 89
Khan (ref_7) 2019; 39
Shinozaki (ref_49) 2011; 459
Keira (ref_48) 2015; 466
Hughes (ref_102) 2006; 59
Mi (ref_31) 2019; 14
Shafizadeh (ref_58) 2010; 41
Corcoran (ref_97) 2014; 34
Yu (ref_86) 2017; 10
Nair (ref_69) 2018; 38
Sun (ref_44) 2014; 7
Kumar (ref_68) 2018; 9
Buckholz (ref_3) 2020; 24
Huynh (ref_22) 2009; 379
Pelaz (ref_15) 2017; 11
Crane (ref_32) 2011; 4
Sun (ref_46) 2015; 8
Ogo (ref_54) 2006; 26
Chen (ref_17) 2014; 55
ref_36
Terada (ref_76) 1994; 25
Wiggers (ref_24) 2014; 29
Razumilava (ref_2) 2014; 383
Alterio (ref_88) 2009; 106
Sahin (ref_72) 2008; 14
Mi (ref_30) 2019; 47
Li (ref_99) 2005; 7
Kodiha (ref_18) 2015; 5
Stang (ref_103) 2010; 25
Muhamad (ref_23) 2018; 13
Itatsu (ref_40) 2009; 174
Li (ref_39) 2017; 77
Gomes (ref_65) 2018; 45
Xu (ref_66) 2019; 38
ref_100
Yoshikawa (ref_56) 2008; 98
ref_101
Driessen (ref_89) 2006; 243
Pastorekova (ref_95) 1997; 112
McKnight (ref_34) 2018; 8
Hicke (ref_83) 2006; 47
Quiros (ref_70) 2017; 1397
Belkouz (ref_8) 2020; 151
Miyamoto (ref_59) 2011; 105
Swietach (ref_90) 2010; 29
Moon (ref_63) 2016; 48
ref_4
Jacobson (ref_38) 2015; 56
References_xml – volume: 362
  start-page: 1273
  year: 2010
  ident: ref_9
  article-title: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0908721
  contributor:
    fullname: Valle
– volume: 3
  start-page: 292
  year: 2013
  ident: ref_13
  article-title: Theranostics and contrast-agents for medical imaging: A pharmaceutical company viewpoint
  publication-title: Quant. Imaging Med. Surg.
  contributor:
    fullname: Idee
– volume: 7
  start-page: 301
  year: 2005
  ident: ref_99
  article-title: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.03.003
  contributor:
    fullname: Li
– volume: 37
  start-page: 3591
  year: 2017
  ident: ref_64
  article-title: Nimotuzumab Inhibits Cholangiocarcinoma Cell Metastasis via Suppression of the Epithelial-Mesenchymal Transition Process
  publication-title: Anticancer Res.
  contributor:
    fullname: Padthaisong
– volume: 25
  start-page: 143
  year: 1994
  ident: ref_76
  article-title: Expression of tenascin, type IV collagen and laminin during human intrahepatic bile duct development and in intrahepatic cholangiocarcinoma
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.1994.tb01570.x
  contributor:
    fullname: Terada
– volume: 56
  start-page: 1310
  year: 2015
  ident: ref_37
  article-title: TGF-beta Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.115.154401
  contributor:
    fullname: Bensch
– volume: 18
  start-page: 991
  year: 2018
  ident: ref_96
  article-title: Targeted therapy for metastatic colorectal cancer
  publication-title: Expert Rev. Anticancer Ther.
  doi: 10.1080/14737140.2018.1502664
  contributor:
    fullname: Price
– volume: 119
  start-page: 993
  year: 2013
  ident: ref_43
  article-title: High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery
  publication-title: Cancer
  doi: 10.1002/cncr.27788
  contributor:
    fullname: Shi
– ident: ref_51
  doi: 10.3390/ijms19041004
– volume: 379
  start-page: 201
  year: 2009
  ident: ref_22
  article-title: Lipid nanocapsules: A new platform for nanomedicine
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2009.04.026
  contributor:
    fullname: Huynh
– volume: 36
  start-page: 986
  year: 2004
  ident: ref_74
  article-title: Tenascins
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2003.12.002
– volume: 9
  start-page: e404
  year: 2018
  ident: ref_68
  article-title: Emerging Therapies in the Management of Advanced-Stage Gastric Cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.00404
  contributor:
    fullname: Kumar
– volume: 98
  start-page: 418
  year: 2008
  ident: ref_56
  article-title: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6604129
  contributor:
    fullname: Yoshikawa
– ident: ref_27
– volume: 3
  start-page: 597
  year: 2010
  ident: ref_42
  article-title: Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma
  publication-title: Mol. Med. Rep.
  contributor:
    fullname: Subimerb
– volume: 105
  start-page: 131
  year: 2011
  ident: ref_59
  article-title: Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2011.199
  contributor:
    fullname: Miyamoto
– volume: 25
  start-page: 603
  year: 2010
  ident: ref_103
  article-title: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
  publication-title: Eur. J. Epidemiol.
  doi: 10.1007/s10654-010-9491-z
  contributor:
    fullname: Stang
– volume: 34
  start-page: 596
  year: 2014
  ident: ref_97
  article-title: Imaging EGFR and HER2 by PET and SPECT: A review
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21299
  contributor:
    fullname: Corcoran
– volume: 47
  start-page: 131
  year: 1986
  ident: ref_75
  article-title: Tenascin: An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis
  publication-title: Cell
  doi: 10.1016/0092-8674(86)90374-0
  contributor:
    fullname: Mackie
– ident: ref_101
  doi: 10.1007/s00259-019-04555-6
– volume: 8
  start-page: 304
  year: 2007
  ident: ref_33
  article-title: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(07)70044-X
  contributor:
    fullname: Divgi
– volume: 26
  start-page: 763
  year: 2006
  ident: ref_54
  article-title: Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma
  publication-title: Anticancer Res.
  contributor:
    fullname: Ogo
– volume: 8
  start-page: 8376
  year: 2015
  ident: ref_46
  article-title: Interleukin-8 is a prognostic indicator in human hilar cholangiocarcinoma
  publication-title: Int. J. Clin. Exp. Pathol.
  contributor:
    fullname: Sun
– volume: 3
  start-page: 33
  year: 2006
  ident: ref_1
  article-title: Cholangiocarcinoma
  publication-title: Nat. Clin. Pract. Gastroenterol. Hepatol.
  doi: 10.1038/ncpgasthep0389
  contributor:
    fullname: Patel
– volume: 112
  start-page: 398
  year: 1997
  ident: ref_95
  article-title: Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts
  publication-title: Gastroenterology
  doi: 10.1053/gast.1997.v112.pm9024293
  contributor:
    fullname: Pastorekova
– volume: 41
  start-page: D377
  year: 2013
  ident: ref_26
  article-title: PANTHER in 2013: Modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gks1118
  contributor:
    fullname: Mi
– ident: ref_4
  doi: 10.1038/s41575-020-0310-z
– volume: 32
  start-page: 700
  year: 2014
  ident: ref_62
  article-title: Characterization of EGFR family gene aberrations in cholangiocarcinoma
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2014.3261
  contributor:
    fullname: Yang
– volume: 283
  start-page: 27799
  year: 2008
  ident: ref_87
  article-title: Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M800938200
  contributor:
    fullname: Hilvo
– volume: 10
  start-page: e211
  year: 2015
  ident: ref_79
  article-title: The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer
  publication-title: Diagn. Pathol.
  doi: 10.1186/s13000-015-0445-3
  contributor:
    fullname: Xu
– volume: 38
  start-page: 6737
  year: 2018
  ident: ref_69
  article-title: Neutrophil Gelatinase-associated Lipocalin as a Theragnostic Marker in Perihilar Cholangiocarcinoma
  publication-title: Anticancer Res.
  doi: 10.21873/anticanres.13043
  contributor:
    fullname: Nair
– volume: 29
  start-page: 6509
  year: 2010
  ident: ref_90
  article-title: New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation
  publication-title: Oncogene
  doi: 10.1038/onc.2010.455
  contributor:
    fullname: Swietach
– volume: 14
  start-page: 7624
  year: 2008
  ident: ref_72
  article-title: Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-08-1547
  contributor:
    fullname: Sahin
– volume: 12
  start-page: 2209
  year: 2011
  ident: ref_5
  article-title: Trends in liver cancer incidence between 1985 and 2009, Khon Kaen, Thailand: Cholangiocarcinoma
  publication-title: Asian Pac. J. Cancer Prev.
  contributor:
    fullname: Wiangnon
– volume: 24
  start-page: 421
  year: 2020
  ident: ref_3
  article-title: Cholangiocarcinoma: Diagnosis and Management
  publication-title: Clin. Liver Dis.
  doi: 10.1016/j.cld.2020.04.005
  contributor:
    fullname: Buckholz
– volume: 14
  start-page: 703
  year: 2019
  ident: ref_31
  article-title: Protocol Update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0)
  publication-title: Nat. Protoc.
  doi: 10.1038/s41596-019-0128-8
  contributor:
    fullname: Mi
– volume: 466
  start-page: 265
  year: 2015
  ident: ref_48
  article-title: An immunohistochemical marker panel including claudin-18, maspin, and p53 improves diagnostic accuracy of bile duct neoplasms in surgical and presurgical biopsy specimens
  publication-title: Virchows Arch.
  doi: 10.1007/s00428-014-1705-4
  contributor:
    fullname: Keira
– volume: 59
  start-page: 1073
  year: 2006
  ident: ref_102
  article-title: Liver fluke-associated and sporadic cholangiocarcinoma: An immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes
  publication-title: J. Clin. Pathol.
  doi: 10.1136/jcp.2005.033712
  contributor:
    fullname: Hughes
– ident: ref_25
– volume: 21
  start-page: 7380
  year: 2001
  ident: ref_71
  article-title: Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.21.21.7380-7390.2001
  contributor:
    fullname: Niimi
– volume: 6
  start-page: S6
  year: 2014
  ident: ref_14
  article-title: Theranostics: A treasured tailor for tomorrow
  publication-title: J. Pharm. Bioallied. Sci.
  doi: 10.4103/0975-7406.137249
  contributor:
    fullname: Jeelani
– volume: 47
  start-page: D607
  year: 2019
  ident: ref_28
  article-title: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gky1131
  contributor:
    fullname: Szklarczyk
– volume: 475
  start-page: 563
  year: 2019
  ident: ref_73
  article-title: Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: Results from a large Caucasian cohort study
  publication-title: Virchows Arch.
  doi: 10.1007/s00428-019-02624-7
  contributor:
    fullname: Dottermusch
– volume: 13
  start-page: 6470
  year: 2007
  ident: ref_55
  article-title: AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v13.i48.6470
  contributor:
    fullname: Schmitz
– volume: 19
  start-page: 3101
  year: 2020
  ident: ref_10
  article-title: Comprehensive genomic profile of cholangiocarcinomas in China
  publication-title: Oncol. Lett.
  contributor:
    fullname: Tian
– volume: 383
  start-page: 2168
  year: 2014
  ident: ref_2
  article-title: Cholangiocarcinoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)61903-0
  contributor:
    fullname: Razumilava
– volume: 106
  start-page: 16233
  year: 2009
  ident: ref_88
  article-title: Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.0908301106
  contributor:
    fullname: Alterio
– ident: ref_100
  doi: 10.1371/journal.pone.0163366
– volume: 110
  start-page: 803
  year: 2018
  ident: ref_104
  article-title: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djy088
  contributor:
    fullname: Sauerbrei
– volume: 9
  start-page: e13261
  year: 2019
  ident: ref_11
  article-title: Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-49860-0
  contributor:
    fullname: Ettrich
– volume: 3
  start-page: 287
  year: 2009
  ident: ref_77
  article-title: The role of tenascin-C in tissue injury and tumorigenesis
  publication-title: J. Cell Commun. Signal.
  doi: 10.1007/s12079-009-0075-1
  contributor:
    fullname: Midwood
– volume: 8
  start-page: e9043
  year: 2018
  ident: ref_34
  article-title: Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab)
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-27454-6
  contributor:
    fullname: McKnight
– volume: 39
  start-page: 19
  year: 2019
  ident: ref_7
  article-title: Cholangiocarcinoma: Epidemiology and risk factors
  publication-title: Liver Int.
  doi: 10.1111/liv.14095
  contributor:
    fullname: Khan
– ident: ref_57
  doi: 10.1186/1471-2407-10-631
– volume: 38
  start-page: 868
  year: 2019
  ident: ref_66
  article-title: HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0485-8
  contributor:
    fullname: Xu
– volume: 5
  start-page: e1701070
  year: 2018
  ident: ref_84
  article-title: Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy
  publication-title: Adv. Sci. (Weinh)
  doi: 10.1002/advs.201701070
  contributor:
    fullname: He
– volume: 5
  start-page: 357
  year: 2015
  ident: ref_18
  article-title: Off to the organelles - killing cancer cells with targeted gold nanoparticles
  publication-title: Theranostics
  doi: 10.7150/thno.10657
  contributor:
    fullname: Kodiha
– volume: 77
  start-page: 2699
  year: 2017
  ident: ref_39
  article-title: Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-3247
  contributor:
    fullname: Li
– volume: 10
  start-page: 293
  year: 2017
  ident: ref_86
  article-title: Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis
  publication-title: Annu. Rev. Anal. Chem. (Palo Alto Calif.)
  doi: 10.1146/annurev-anchem-061516-045205
  contributor:
    fullname: Yu
– volume: 459
  start-page: 73
  year: 2011
  ident: ref_49
  article-title: Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma
  publication-title: Virchows Arch.
  doi: 10.1007/s00428-011-1092-z
  contributor:
    fullname: Shinozaki
– volume: 3
  start-page: 448
  year: 2013
  ident: ref_21
  article-title: PET imaging of inflammation biomarkers. Theranostics
  publication-title: Theranostics
  doi: 10.7150/thno.6592
  contributor:
    fullname: Wu
– volume: 48
  start-page: 43
  year: 2019
  ident: ref_78
  article-title: Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma
  publication-title: Pancreas
  doi: 10.1097/MPA.0000000000001195
  contributor:
    fullname: Leppanen
– volume: 11
  start-page: 2313
  year: 2017
  ident: ref_15
  article-title: Diverse Applications of Nanomedicine
  publication-title: ACS Nano.
  doi: 10.1021/acsnano.6b06040
  contributor:
    fullname: Pelaz
– volume: 48
  start-page: 35
  year: 2016
  ident: ref_63
  article-title: EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma
  publication-title: Pathology
  doi: 10.1016/j.pathol.2015.11.011
  contributor:
    fullname: Moon
– volume: 55
  start-page: 1919
  year: 2014
  ident: ref_17
  article-title: Theranostic nanoparticles
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.114.146019
  contributor:
    fullname: Chen
– volume: 59
  start-page: 1241
  year: 2012
  ident: ref_60
  article-title: Clinicopathological significance of E-cadherin, beta-catenin and epidermal growth factor receptor expression in intrahepatic cholangiocarcinoma
  publication-title: Hepatogastroenterology
  contributor:
    fullname: Gu
– volume: 7
  start-page: 6157
  year: 2014
  ident: ref_44
  article-title: High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma
  publication-title: Int. J. Clin. Exp. Pathol.
  contributor:
    fullname: Sun
– volume: 7
  start-page: 118
  year: 2008
  ident: ref_35
  article-title: Optical imaging of matrix metalloproteinase-7 activity in vivo using a proteolytic nanobeacon
  publication-title: Mol. Imaging
  doi: 10.2310/7290.2008.00010
  contributor:
    fullname: Scherer
– volume: 1397
  start-page: 66
  year: 2017
  ident: ref_70
  article-title: Intestinal epithelial claudins: Expression and regulation in homeostasis and inflammation
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/nyas.13360
  contributor:
    fullname: Quiros
– volume: 29
  start-page: 1582
  year: 2014
  ident: ref_24
  article-title: Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
  publication-title: J. Gastroenterol. Hepatol.
  doi: 10.1111/jgh.12620
  contributor:
    fullname: Wiggers
– ident: ref_52
  doi: 10.1186/s12885-019-5429-3
– volume: 8
  start-page: 38022
  year: 2017
  ident: ref_92
  article-title: Combination therapy in combating cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16723
  contributor:
    fullname: Homayouni
– volume: 74
  start-page: 597
  year: 2019
  ident: ref_105
  article-title: Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma
  publication-title: Histopathology
  doi: 10.1111/his.13797
  contributor:
    fullname: Espinoza
– volume: 19
  start-page: e49
  year: 2019
  ident: ref_67
  article-title: Prediction for early recurrence of intrahepatic mass-forming cholangiocarcinoma: Quantitative magnetic resonance imaging combined with prognostic immunohistochemical markers
  publication-title: Cancer Imaging
  doi: 10.1186/s40644-019-0234-4
  contributor:
    fullname: Zhao
– volume: 13
  start-page: 3921
  year: 2018
  ident: ref_23
  article-title: Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S165210
  contributor:
    fullname: Muhamad
– volume: 45
  start-page: e1826
  year: 2018
  ident: ref_65
  article-title: Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: Predictive factors and survival
  publication-title: Rev. Col. Bras. Cir.
  doi: 10.1590/0100-6991e-20181826
  contributor:
    fullname: Gomes
– volume: 56
  start-page: 616
  year: 2015
  ident: ref_38
  article-title: PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.114.149484
  contributor:
    fullname: Jacobson
– ident: ref_93
– volume: 151
  start-page: e102975
  year: 2020
  ident: ref_8
  article-title: Advances in adjuvant therapy of biliary tract cancer: An overview of current clinical evidence based on phase II and III trials
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2020.102975
  contributor:
    fullname: Belkouz
– volume: 174
  start-page: 829
  year: 2009
  ident: ref_40
  article-title: Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha
  publication-title: Am. J. Pathol.
  doi: 10.2353/ajpath.2009.080012
  contributor:
    fullname: Itatsu
– volume: 72
  start-page: 403
  year: 2007
  ident: ref_82
  article-title: Tenascin-C expression and its prognostic significance in colorectal cancer
  publication-title: Oncology
  doi: 10.1159/000113490
  contributor:
    fullname: Lundin
– volume: 127
  start-page: 64
  year: 2019
  ident: ref_81
  article-title: The role of Tenascin-C and Twist1 in gastric cancer: Cancer progression and prognosis
  publication-title: APMIS
  doi: 10.1111/apm.12919
  contributor:
    fullname: Qi
– volume: 1804
  start-page: 404
  year: 2010
  ident: ref_91
  article-title: Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbapap.2009.07.027
  contributor:
    fullname: Supuran
– volume: 89
  start-page: 1261
  year: 2009
  ident: ref_41
  article-title: Fascin is involved in tumor necrosis factor-alpha-dependent production of MMP9 in cholangiocarcinoma
  publication-title: Lab. Invest.
  doi: 10.1038/labinvest.2009.89
  contributor:
    fullname: Onodera
– volume: 27
  start-page: 145
  year: 2014
  ident: ref_85
  article-title: Adhiron: A stable and versatile peptide display scaffold for molecular recognition applications
  publication-title: Protein Eng. Des. Sel.
  doi: 10.1093/protein/gzu007
  contributor:
    fullname: Tiede
– volume: 41
  start-page: 485
  year: 2010
  ident: ref_58
  article-title: Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder
  publication-title: Hum. Pathol.
  doi: 10.1016/j.humpath.2009.10.002
  contributor:
    fullname: Shafizadeh
– volume: 243
  start-page: 334
  year: 2006
  ident: ref_89
  article-title: Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas
  publication-title: Ann. Surg.
  doi: 10.1097/01.sla.0000201452.09591.f3
  contributor:
    fullname: Driessen
– volume: 5
  start-page: 2839
  year: 2014
  ident: ref_61
  article-title: Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.1943
  contributor:
    fullname: Simbolo
– volume: 41
  start-page: 985
  year: 2014
  ident: ref_94
  article-title: Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: In vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma
  publication-title: Eur. J. Nucl. Med. Mol. Imaging
  doi: 10.1007/s00259-013-2679-1
  contributor:
    fullname: Cheal
– volume: 44
  start-page: 638
  year: 2018
  ident: ref_47
  article-title: High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients
  publication-title: Eur. J. Surg. Oncol.
  doi: 10.1016/j.ejso.2018.01.012
  contributor:
    fullname: Park
– volume: 21
  start-page: 195
  year: 2015
  ident: ref_45
  article-title: The expression of S100A4 protein in human intrahepatic cholangiocarcinoma: Clinicopathologic significance and prognostic value
  publication-title: Pathol Oncol. Res.
  doi: 10.1007/s12253-014-9806-6
  contributor:
    fullname: Tian
– volume: 8
  start-page: 66865
  year: 2017
  ident: ref_80
  article-title: Tenascin-C and fibronectin in normal esophageal mucosa, Barrett’s esophagus, dysplasia and adenocarcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19196
  contributor:
    fullname: Leppanen
– volume: 16
  start-page: e48
  year: 2015
  ident: ref_98
  article-title: Targeted Therapy in Biliary Tract Cancers
  publication-title: Curr. Treat. Options Oncol.
  doi: 10.1007/s11864-015-0366-0
  contributor:
    fullname: Merla
– volume: 4
  start-page: 71
  year: 2011
  ident: ref_32
  article-title: Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool
  publication-title: Transl. Oncol.
  doi: 10.1593/tlo.10220
  contributor:
    fullname: Crane
– volume: 116
  start-page: 2826
  year: 2016
  ident: ref_16
  article-title: Nanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy
  publication-title: Chem. Rev.
  doi: 10.1021/acs.chemrev.5b00148
  contributor:
    fullname: Chen
– volume: 11
  start-page: 7967
  year: 2005
  ident: ref_19
  article-title: The progress and promise of molecular imaging probes in oncologic drug development
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-1302
  contributor:
    fullname: Kelloff
– volume: 9
  start-page: 90
  year: 2015
  ident: ref_106
  article-title: Tenascin-C in cardiovascular remodeling: Potential impact for diagnosis, prognosis estimation and targeted therapy
  publication-title: Cell Adhes. Migr.
  doi: 10.1080/19336918.2014.1000075
  contributor:
    fullname: Franz
– ident: ref_29
– volume: 76
  start-page: 293
  year: 2009
  ident: ref_50
  article-title: A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model
  publication-title: Oncology
  doi: 10.1159/000207506
  contributor:
    fullname: Iguchi
– volume: 8
  start-page: 862
  year: 2015
  ident: ref_53
  article-title: CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma
  publication-title: Int. J. Clin. Exp. Pathol.
  contributor:
    fullname: Gu
– volume: 32
  start-page: 395
  year: 2016
  ident: ref_6
  article-title: Epidemiology and Risk Factors of Cholangiocarcinoma
  publication-title: Visc. Med.
  doi: 10.1159/000453013
  contributor:
    fullname: Kirstein
– volume: 37
  start-page: 50
  year: 2009
  ident: ref_12
  article-title: Toward theragnostics
  publication-title: Crit. Care Med.
  doi: 10.1097/CCM.0b013e3181921349
  contributor:
    fullname: Pene
– volume: 47
  start-page: 668
  year: 2006
  ident: ref_83
  article-title: Tumor targeting by an aptamer
  publication-title: J. Nucl. Med.
  contributor:
    fullname: Hicke
– volume: 47
  start-page: D419
  year: 2019
  ident: ref_30
  article-title: PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gky1038
  contributor:
    fullname: Mi
– ident: ref_36
  doi: 10.1371/journal.pone.0187767
– volume: 12
  start-page: 187
  year: 2015
  ident: ref_20
  article-title: Nanoparticle-Based Targeted Therapeutics in Head-And-Neck Cancer
  publication-title: Int. J. Med. Sci.
  doi: 10.7150/ijms.10083
  contributor:
    fullname: Wu
SSID ssj0000331767
Score 2.2817538
SecondaryResourceType review_article
Snippet Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers...
Bile duct cancers are rare cancers that have poor prospects and limited treatment options. Recently, significant advances have been made in the field of...
Simple SummaryBile duct cancers are rare cancers that have poor prospects and limited treatment options. Recently, significant advances have been made in the...
SourceID pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 2817
SubjectTerms Bile ducts
Bioinformatics
Biomarkers
Cancer
Cancer therapies
Cholangiocarcinoma
Diagnosis
Disease
Gelatinase B
Genes
Genetic translation
Growth factors
Health aspects
Medical prognosis
Nanoparticles
Nanotechnology
Ontology
Proteins
Rare diseases
Review
Reviews
Systematic review
SummonAdditionalLinks – databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB50BfEivl1dJYIHL8XNJk1TL7KKIoIiPsBbaR7VPdjqdv3_zrTdrutBepwEykwy833JZAbgWBpvXMrDwKD3Q4KSuSA1ggdZ33KjlLXO02vku3t18yJvX8PX5sCtbNIqpz6xctSusHRGfopEBpE1BqPB-edXQF2j6Ha1aaGxCEsDLrTuwNLF1f3DY3vK0hcYH1VU1_QRyO9PLSlzXFZ1s3TVpmwWjv465V9RaT5j8lcIul6D1QY7smFt7HVY8PkGLN81t-Ob8FAFHkpuy9_Yxaj4oNSbccmKjF0Shc3fRhi5xjgYRQzRKnum11d5UY7KMzZkT21VZ1ZfGWzBy_XV8-VN0HRMCKyU8SSwSmeOR05IkyEx01pYpL5cIIzx1AId7dLX0nPh4tCmofJWGydVKixP4zDKxDZ08iL3u8AGNo69C8NMSSt9HBn8ELpI5b1QPrZdOJkqLvmsC2MkSChIx8kfHXehR4pNaMug9iwuYJsMkfgg1VFaoHiq8KTZQGUyM3cXjloxzaSksNwX3zgGqSXiEUR0Xdip7dP-ihAEfiKcHc1Zrh1AZbXnJfnovSqvTVlCEY_3_v-tfVgZEPWuUkd60JmMv_0B4pOJOWwW4Q_hkegz
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwEA46QXwRfzudEsEHX6rLkqatIDKHYwgTwQ32Vpo0nQNttd1A_3vv2m5uY0gfL4H0uzT3ffRyR8ilUEaFAbMtBacfCJQotALFmRXVNVNSah0avI3cfZadvnga2IO_dkAlgNlKaYf9pPrp-_X31889fPB3qDhBst9oxCfN8lJYLnPWyUYDwiLmd3VLrp8fyxxCpXSK8j6r5i1EpuXzeS5ALSZPzkWj9g7ZLmkkbRZ-3yVrJt4jm93yR_k-ecljEOa5xUP6MEo-MAsnzWgS0Ra-cjwcQRBLYTCYKBBX2sOLWHGSjbJb2qSvswLPtPh7cED67cdeq2OVzRMsLYQ3trR0o5A5IRcqAo3mulyDCmYcGI3BbujgororDOOhZ-vAlka7KhQy4JoFnu1E_JBU4iQ2x4Q2tOeZ0LYjKbQwnqPgARYjpDFcGk9XydUUOP-zqJHhg7ZAjP0ljKukhsD66E9AT8Ne1n4TNBCoHulyME8B96dbwQcJC5oKaEijSi5mZpyJ-WGxSSYwBlQmUBMgd1VyVPhnthTOkQc5MNtZ8NxsAFbYXrTEo7e80jYmDDnMO_l_Wadkq4EqPM8iqZHKOJ2YM6AqY3Web8FfKlTqpw
  priority: 102
  providerName: Scholars Portal
Title Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review
URI https://www.ncbi.nlm.nih.gov/pubmed/33007872
https://www.proquest.com/docview/2547532442
https://www.proquest.com/docview/2448406644
https://pubmed.ncbi.nlm.nih.gov/PMC7601719
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La-MwEB6aFJa9lLb7cpsGLexhL26qSJbt3tLQBwspYbeF3Iw1llvDRi5x-v878iMkPRaDL5JAzIw034c-jQB-SW10lvLA17T7EUHJMz_Vgvv5BXKtFGJm3G3k2b26e5R_FsFiD4LuLkwt2kddnNv_y3NbPNfaypcljjqd2Gg-mzodR8jjUQ96lH63KHq9_QpKiSpsyvgIovQjdPZbVXWprIi7Z_eIxFNqDMc7yej9lryVk3b1klsJ6OYQDlrkyCbNDI9gz9hj-DRrz8a_wLxOO07aZp_YVVEunfBmVbEyZ1NHYO1TQXlrRZ2piRFWZQ_u7pUtq6K6ZBP2b1PTmTUHBl_h8eb6YXrnt-8l-ChlvPZRRXnGw0xInRMtiyKBRHy5IBBj3APo5JWLSBousjjANFAGI51JlQrkaRyEufgGfVta8wPYGOPYZEGQK4nSxKGmj4CLVMYIZWL04HdnuOSlKYuREJ1w5k7emduDgTNs4hYMWQ8pfDGZEO0hoqMiQc2dwZN2-VQJsVaiUYQ8xh783DS7kU4SZk35Sn2IWBIaITznwffGP5updP71INzx3KaDK6q920KxVhfXbmPr5MMjT-Hz2HHyWlMygP569WrOCLis9RD2r67v53-H0LtdcPrPZDSsg_cNXFLzLA
link.rule.ids 230,314,727,780,784,885,2221,21388,24318,27924,27925,33744,33745,43805,53791,53793,74302
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZgSMAF8WY8g8SBS8W6pGnLBQ0EGo9NCIbErWoeHTvQwjr-P3bbFcYB9ehEquzE_r7EsQFOhLLKxK7nKPR-SFAS48SKu07S0q6SUmtj6TVyry-7L-Lu1XutDtzyKq1y6hMLR20yTWfkZ0hkEFljMGpffHw61DWKblerFhrzsECV070GLFxe9x-f6lOWFsf4KP2ypg9Hfn-mSZnjvKibFRRtyn7C0V-n_CsqzWZM_gpBN6uwUmFH1imNvQZzNl2HxV51O74Bj0XgoeS2dMguR9k7pd6Mc5Yl7IoobDocYeQa42AUMUSrbECvr9IsH-XnrMOe66rOrLwy2ISXm-vBVdepOiY4Wohw4mgZJMb1DRcqQWIWBFwj9XU5whhLLdDRLq1AWJeb0NOxJ60OlBEy5tqNQ89P-BY00iy1O8DaOgyt8bxECi1s6Cv8ELoIaS2XNtRNOJ0qLvooC2NESChIx9EfHTdhnxQb0ZZB7WlcwDrqIPFBqiMDjuKpwqNqA-XRj7mbcFyLaSYlhaU2-8IxSC0RjyCia8J2aZ_6Vzgn8OPjbH_GcvUAKqs9K0lHb0V5bcoS8t1w9__fOoKl7qD3ED3c9u_3YLlNNLxII9mHxmT8ZQ8Qq0zUYbUgvwHewOsb
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT-MwEB5BkRCXFSyv8loj7YFL1KZ2nGQvqDwqHktV8ZC4RfEjpYdNoCn_f2cSN1AOKEfbkjVje74v_jwD8Fsoq0zqB57C0w8JSma8VHHfy7raV1JqbSy9Rr4byqsncfMcPDv9U-lklfMzsTqoTaHpH3kHiQwiawxGvU7mZBGji8Hp65tHFaToptWV01iGFYyK3V4LVs4uh6P75o9Ll2OslGGd34cj1-9oMuy0rHJoRVXJso_Q9PWA_hShFtWTn8LRYB1-OBzJ-rXjN2DJ5j9h9c7dlG_CqApCJHTLx-xsUvwjGc60ZEXGzonO5uMJRrEpdsYmhsiVPdJLrLwoJ-Uf1mcPTYZnVl8fbMHT4PLx_Mpz1RM8LUQ887SMMuOHhguVIUmLIq6RBvscIY2lcujoo24krM9NHOg0kFZHygiZcu2ncRBmfBtaeZHbXWA9HcfWBEEmhRY2DhV-CGOEtJZLG-s2nMwNl7zWSTISJBdk4-SLjdtwQIZNaPug9TQuZp30kQQh7ZERx-a5wRO3mcrkw_VtOG6aaSQJxHJbvGMfpJmITRDdtWGn9k8zFc4JCIU4OlzwXNOBUmwvtuSTlyrVNimGQj_e-35av2AV12Ly93p4uw9rPWLklaLkAFqz6bs9RNgyU0duPf4HoVLvSA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Translating+Biomarkers+of+Cholangiocarcinoma+for+Theranosis%3A+A+Systematic+Review&rft.jtitle=Cancers&rft.au=Wijetunga%2C+Imeshi&rft.au=McVeigh%2C+Laura+E&rft.au=Charalambous%2C+Antonia&rft.au=Antanaviciute%2C+Agne&rft.date=2020-09-30&rft.pub=MDPI+AG&rft.eissn=2072-6694&rft.volume=12&rft.issue=10&rft.spage=2817&rft_id=info:doi/10.3390%2Fcancers12102817&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon